TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06533098: A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT06533098 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06533098 Rescue Dossier →